Recombinant human deoxyribonuclease I

Thins and loosens mucus in the airways

Phase of research

FDA-/EMA-approved for Cystic Fibrosis

How it helps

Mucociliary Clearance

General information

N/A

Synonyms

rhDNase, Dornase Alfa

Marketed as

Dietary sources

N/A

Structure image not available

N/A

Drug-Mutation Relation

results for R352Q / G542X
See all data on Recombinant human deoxyribonuclease I

Treats

Mutation Link Tested on Impact factor Notes
General effect The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. humans 5.90
General effect Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis humans N/A As effective as Hypertonic Saline.
General effect Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis humans N/A
General effect Effects of 12-Week Administration of Dornase Alfa in Patients with Advanced Cystic Fibrosis Lung Disease humans 2.34
General effect Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. humans 6.53 As effective as mannitol.
General effect DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: influence of treatment with dornase alpha. humans 1.59
General effect A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. humans 3.54
General effect Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. humans 13.25 More effective than hypertonic saline.
General effect Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis. humans N/A

Does not treat

Mutation Link Tested on Impact factor Notes